Determination of lower cut‐off levels of adalimumab associated with biochemical remission in Crohn's disease-Reference-Cited by-同舟云学术

Determination of lower cut‐off levels of adalimumab associated with biochemical remission in Crohn's disease

Published:2019-10-06 Issue:3 Volume:4 Page:410-416
ISSN:2397-9070
Container-title:JGH Open
language:en
Short-container-title:JGH Open

Author:

Carlsen Arne¹²^ORCID,Omdal Roald²³,Karlsen Lars¹,Kvaløy Jan Terje⁴⁵,Aabakken Lars⁶,Steinsbø Øyvind¹²,Bolstad Nils⁷,Warren David⁷,Lundin Knut Erik Aslaksen⁶⁸,Grimstad Tore¹²^ORCID

Affiliation:

1. Gastroenterology Unit, Department of Internal Medicine Stavanger University Hospital Stavanger Norway

2. Department of Clinical Science, Faculty of Medicine University of Bergen Bergen Norway

3. Clinical Immunology Unit, Department of Internal Medicine Stavanger University Hospital Stavanger Norway

4. Department of Mathematics and Physics University of Stavanger Stavanger Norway

5. Research Department Stavanger University Hospital Stavanger Norway

6. Department of Transplantation Medicine Oslo University Hospital Rikshospitalet Oslo Norway

7. Department of Medical Biochemistry Oslo University Hospital Radiumhospitalet Oslo Norway

8. KG Jebsen Celiac Disease Research Centre University of Oslo Oslo, Norway

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jgh3.12266

Reference39 articles.

1. Crohn's disease

2. Long-Term Evolution of Disease Behavior of Crohn's Disease

3. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management

4. Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial

5. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease;American Journal of Gastroenterology;2021-08-13